Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI) Jason Luoma, Ph.D., of Portland Psychotherapy, is the sponsor and Principal Investigator for SAMATI, an exploratory study to investigate the …
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
On July 21, 2022, a general medical and psychiatric practice in Steinheim, Germany, released a statement about their use of cannabis to treat patients with symptoms of posttraumatic stress disorder (PTSD). …
Zendo Project Prepares Provide Peer Support at Burning Man 2022
The Zendo Project is headed to Burning Man next month to provide psychedelic peer support, harm reduction, and education for the first time in three years! Our application is now closed, and we received …
June 2022 Giving Report: Donors Give Over $373,000 to Psychedelic Research and Education
In June 2022, over 1,000 donors gave $373,433 in donations and pledges. We are so grateful to these supporters who advance our shared vision of creating safe and legal opportunities for the beneficial …
MDMA Therapy Training Program Update: July 2022
In June 2022, the MDMA Therapy Training Team delivered two more trainings, including a week-long in-person training retreat in New York and a week-long training in California in collaboration with the …
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
Yesterday, a letter from the U.S. Department of Health and Human Services was made public describing the Food and Drug Administration’s “anticipated approval…within approximately 24 months” of …
MDMA and Healing a Dis-regulated Nervous System
“I have worked with a lot of medicine on my healing journey. Dozens of ayahuasca ceremonies. Extensive experience with psilocybin, ketamine, kambo, and deep sessions with 5-MeO. While I’ve had …
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three …
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience …
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
Psychedelic Fundamentals is the initial offering in the new MAPS Digital Learning program introducing learners to the most important aspects of psychedelic history, research, uses, and harm reduction The …